S141: ELICITING ANTI-TUMOR T CELL ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH BISPECIFIC ANTIBODY-BASED COMBINATION THERAPY

Autor: D. Papazoglou, L. Ysebaert, N. Ioannou, B. Apollonio, P. Patten, S. Herter, M. Bacac, A. Deutsch, C. Klein, A. Vardi, A. Quillet-Mary, A. Ramsay

Publikováno v: HemaSphere, Vol 6, Pp 42-43 (2022)

Externí odkaz: https://doaj.org/article/050e149ab53a44e5a3ddc7116344127e

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia.

Autor: Wegmann R; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland., Bonilla X; Department of Computer Science, ETH Zurich, Zurich, Switzerland., Casanova R; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland., Chevrier S; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland., Coelho R; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Esposito C; Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland., Ficek-Pascual J; Department of Computer Science, ETH Zurich, Zurich, Switzerland., Goetze S; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.; ETH PHRT Swiss Multi-Omics Center (SMOC), Lausanne, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Gut G; Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland., Jacob F; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Jacobs A; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland., Kuipers J; Department of Biosystems Science and Engineering, ETH Zurich, Zurich, Switzerland., Lischetti U; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Mena J; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland., Milani ES; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland., Prummer M; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; NEXUS Personalized Health Technologies, ETH Zurich, Zurich, Switzerland., Del Castillo JS; Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland., Singer F; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; NEXUS Personalized Health Technologies, ETH Zurich, Zurich, Switzerland., Sivapatham S; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland., Toussaint NC; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; NEXUS Personalized Health Technologies, ETH Zurich, Zurich, Switzerland.; Swiss Data Science Center, ETH Zürich, Zurich, Switzerland., Vilinovszki O; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland., Wildschut MHE; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland., Thavayogarajah T; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland., Malani D; Harvard Medical School and Dana-Farber Cancer Institute, Boston, USA., Aebersold R; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland., Bacac M; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Beerenwinkel N; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; Department of Biosystems Science and Engineering, ETH Zurich, Zurich, Switzerland., Beisel C; Department of Biosystems Science and Engineering, ETH Zurich, Zurich, Switzerland., Bodenmiller B; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland., Heinzelmann-Schwarz V; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Koelzer VH; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.; University of Zurich, Faculty of Medicine, Zurich, Switzerland., Levesque MP; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Moch H; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.; University of Zurich, Faculty of Medicine, Zurich, Switzerland., Pelkmans L; Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland., Rätsch G; Department of Computer Science, ETH Zurich, Zurich, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; AI Center at ETH Zurich, Zurich, Switzerland., Tolnay M; Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland., Wicki A; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.; University of Zurich, Faculty of Medicine, Zurich, Switzerland., Wollscheid B; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland., Manz MG; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland. markus.manz@usz.ch., Snijder B; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland. snijder@imsb.biol.ethz.ch.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland. snijder@imsb.biol.ethz.ch., Theocharides APA; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland. alexandre.theocharides@usz.ch.

Publikováno v: Nature communications [Nat Commun] 2024 Oct 30; Vol. 15 (1), pp. 9402. Date of Electronic Publication: 2024 Oct 30.

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.

Autor: Sam J; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Hofer T; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Kuettel C; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Claus C; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Thom J; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Herter S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Georges G; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Korfi K; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Lechmann M; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Eigenmann MJ; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Marbach D; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Jamois C; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Lechner K; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Krishnan SM; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Gaillard B; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Marinho J; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Kronenberg S; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Kunz L; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Wilson S; Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Welwyn Garden City, United Kingdom., Briner S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Gebhardt S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Varol A; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Appelt B; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Nicolini V; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Speziale D; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Bez M; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Bommer E; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Eckmann J; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Hage C; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Limani F; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Jenni S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Schoenle A; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Le Clech M; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Vallier JP; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Colombetti S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Bacac M; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Gasser S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Klein C; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland., Umaña P; Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.

Publikováno v: Blood [Blood] 2024 May 23; Vol. 143 (21), pp. 2152-2165.

Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.

Autor: Papazoglou D; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom., Wang XV; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.; Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA., Shanafelt TD; School of Medicine, Stanford University, Stanford, CA., Lesnick CE; Department of Immunology, Mayo Clinic, Rochester, MN., Ioannou N; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom., De Rossi G; Institute of Ophthalmology, University College London, London, United Kingdom., Herter S; Discovery Oncology, Roche Innovation Center Zürich, Schlieren, Switzerland., Bacac M; Discovery Oncology, Roche Innovation Center Zürich, Schlieren, Switzerland., Klein C; Discovery Oncology, Roche Innovation Center Zürich, Schlieren, Switzerland., Tallman MS; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY., Kay NE; Department of Immunology, Mayo Clinic, Rochester, MN., Ramsay AG; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.

Publikováno v: Blood [Blood] 2024 Jan 04; Vol. 143 (1), pp. 57-63.

Explainable machine learning for profiling the immunological synapse and functional characterization of therapeutic antibodies.

Autor: Shetab Boushehri S; Institute of AI for Health, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.; Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.; Technical University of Munich, Department of Mathematics, Munich, Germany.; Data & Analytics (D&A), Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Munich, Germany., Essig K; Large Molecule Research (LMR), Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Munich, Germany., Chlis NK; Large Molecule Research (LMR), Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Munich, Germany., Herter S; Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Zurich, Switzerland., Bacac M; Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Zurich, Switzerland., Theis FJ; Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.; Technical University of Munich, Department of Mathematics, Munich, Germany., Glasmacher E; Research and Early Development (RED), Roche Diagnostics Solutions, Roche Innovation Center Munich, Munich, Germany. elke.glasmacher@roche.com., Marr C; Institute of AI for Health, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. carsten.marr@helmholtz-munich.de.; Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. carsten.marr@helmholtz-munich.de., Schmich F; Data & Analytics (D&A), Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Munich, Germany. fabian.schmich@roche.com.

Publikováno v: Nature communications [Nat Commun] 2023 Nov 30; Vol. 14 (1), pp. 7888. Date of Electronic Publication: 2023 Nov 30.